Bio Rad Laboratories Inc (NYSE:BIO)
| 460.57 Delayed Data As of Mar 24 |  +4.25 / +0.93%Today’s Change | 344.63 Today|||52-Week Range 607.54 | +9.53% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | 113.1M | 28.1M | 122.2M | 365.6M | |
| Depreciation | 131.8M | 142.9M | 148.7M | 138.1M | ||
| Total Other Cash Flow | 7.1M | 80.5M | 31.8M | -300.1M | ||
| Funds From Operations | 245.6M | 200.1M | 220.8M | 324.5M | ||
| Funds From/For Other Operating Expenses | 59.4M | -16.3M | 116.9M | 39.0M | ||
| Net Cash Flow - Operating Activities | 186.2M | 216.4M | 103.9M | 285.5M | ||
| Investing | Increase In Investments | -294.5M | -292.2M | -360.3M | -370.8M | |
| Decrease In Investments | 249.5M | 219.9M | 299.8M | 302.3M | ||
| Capital Expenditures | -112.0M | -141.4M | -111.3M | -129.8M | ||
| Fixed Asset Disposal | 79.0K | 398.0K | 86.0K | 11.3M | ||
| Other Investing - Uses | -4.4M | 0.00 | 0.00 | 0.00 | ||
| Net Cash Flow Investing | -162.7M | -213.5M | -175.6M | -187.0M | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 0.00 | 37.0K | 0.00 | 0.00 | ||
| Long Term Debt Reduction | -282.0K | -303.0K | -352.0K | -3.0M | ||
| Net Proceeds Stock Sale | 8.2M | 11.3M | 7.3M | 14.1M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | -2.9M | -48.9M | ||
| Common Dividends | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | 3.6M | 1.5M | 0.00 | 0.00 | ||
| Other Uses - Financing | 3.0M | 3.5M | 3.7M | 10.9M | ||
| Net Cash Flow - Financing | 8.6M | 9.0M | 341.0K | -48.7M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | 16.4M | -12.9M | -1.1M | -655.0K | |
| Net Change In Cash | 32.1M | 11.9M | -71.3M | 49.8M | ||
